BioArctic AB (BIOAb)

Currency in SEK
216.0000
-1.4000(-0.64%)
Closed·
BIOAb Scorecard
Full Analysis
Net income is expected to grow this year
BIOAb is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
212.0000218.2000
52 wk Range
137.7000271.4000
Key Statistics
Prev. Close
216
Open
217
Day's Range
212-218.2
52 wk Range
137.7-271.4
Volume
110.36K
Average Volume (3m)
246.4K
1-Year Change
36.97%
Book Value / Share
21.85
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOAb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
287.6000
Upside
+33.15%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

BioArctic AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

BioArctic AB Company Profile

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Employees
116
Market
Sweden

Compare BIOAb to Peers and Sector

Metrics to compare
BIOAb
Peers
Sector
Relationship
P/E Ratio
21.2x−9.8x−0.5x
PEG Ratio
0.03−0.200.00
Price/Book
9.9x6.8x2.6x
Price / LTM Sales
12.6x43.2x3.3x
Upside (Analyst Target)
29.6%9.0%42.9%
Fair Value Upside
Unlock7.4%6.2%Unlock

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 287.6000
(+33.15% Upside)

Earnings

Latest Release
May 21, 2025
EPS / Forecast
11.55 / 5.88
Revenue / Forecast
1.29B / 1.05B
EPS Revisions
Last 90 days

BIOAb Income Statement

People Also Watch

73.3400
PRY
-0.78%
8.020
STLAM
-0.82%
16.670
BMED
-0.06%
322.6
NOVOb
-0.12%
273.00
SOBIV
+0.07%

FAQ

What Stock Exchange Does BioArctic Trade On?

BioArctic is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for BioArctic?

The stock symbol for BioArctic is "BIOAb."

What Is the BioArctic Market Cap?

As of today, BioArctic market cap is 19.12B.

What Is BioArctic's Earnings Per Share (TTM)?

The BioArctic EPS (TTM) is 10.21.

When Is the Next BioArctic Earnings Date?

BioArctic will release its next earnings report on 27 Aug 2025.

From a Technical Analysis Perspective, Is BIOAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has BioArctic Stock Split?

BioArctic has split 0 times.

How Many Employees Does BioArctic Have?

BioArctic has 116 employees.

What is the current trading status of BioArctic (BIOAb)?

As of 12 Aug 2025, BioArctic (BIOAb) is trading at a price of 216.00, with a previous close of 216.00. The stock has fluctuated within a day range of 212.00 to 218.20, while its 52-week range spans from 137.70 to 271.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.